Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
August 11, 2025Journal of Clinical Pharmacy and TherapeuticsOpen Access

Pharmacokinetics/Pharmacodynamics and Therapeutic Drug Monitoring of Ceftazidime/Avibactam in Patients With Gram‐Negative Bacterial Infections

View Full Paper
Ask AI
Bookmark
Share

Authors

RHRuiying HanDSDan SunYZYing Zhang

Discussion

Loading...

Member takes

Overview

Observational study characterized ceftazidime/avibactam concentrations in infected patients, indicating effective therapeutic monitoring may improve outcomes.

Key Points

  • Cmin of ceftazidime and avibactam varied significantly among patients, with higher levels noted in those with renal issues.
  • Optimal joint PK/PD target achieved in 69.6% of patients with infection, reflecting successful drug regimen.
  • Retrospective observational study analyzed 39 patients undergoing ceftazidime/avibactam therapy for river-target resistant infections.
  • Study suggests effective therapeutic drug monitoring could enhance clinical cure rates for gram-negative bacterial infections.

Cite This Study

Han et al. (2025) studied this question.

synapsesocial.com/papers/68c2354db210217d64770655https://doi.org/10.1155/jcpt/6674305
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Ceftazidime-Avibactam for the Treatment of Carbapenem-Resistant Organisms: A Prospective, Observational, Single-Center Study2025
  2. 2Model-informed individualized administration of ceftazidime–avibactam in critically ill patients: population pharmacokinetics studies and a parametric time-to-event analysis2025
  3. 3PK/PD study of ceftazidime/avibactam in patients with severe intra-abdominal infections treated by continuous veno–venous hemofiltration2025
  4. 4Global susceptibility profiles and potential resistance mechanisms of ceftazidime–avibactam-resistant, non-carbapenemase-producing carbapenem-resistant Enterobacterales: 2020–23 data from the Antimicrobial Testing Leadership and Surveillance2025 · 1 citations
  5. 5Ceftazidime–Avibactam Pharmacokinetic Comparative In Vivo/In Vitro Study in a Critically Ill Children Under High‐Volume Continuous Venovenous Hemodiafiltration2025